دورية أكاديمية

Sirolimus-induced pneumonitis after renal transplantation: a single-center experience

التفاصيل البيبلوغرافية
العنوان: Sirolimus-induced pneumonitis after renal transplantation: a single-center experience
المساهمون: H.S. Lee, K.H. Huh, Y.S. Kim, M.S. Kim, H.J. Kim, S.I. Kim, D.J. Joo, Kim, Yu Seun, Lee, Hyung Keun, Joo, Dong Jin, Huh, Kyu Ha, Kim, Myoung Soo, Kim, Soon Il
سنة النشر: 2012
مصطلحات موضوعية: Adult, Analysis of Variance, Drug Monitoring, Female, Graft Rejection/immunology, Graft Rejection/prevention & control, Graft Survival/drug effects, Humans, Immunosuppressive Agents/adverse effects, Immunosuppressive Agents/blood, Immunosuppressive Agents/pharmacokinetics, Kidney Transplantation*/immunology, Lung Diseases, Interstitial/chemically induced, Interstitial/diagnosis, Interstitial/therapy, Male, Middle Aged, Republic of Korea, Retrospective Studies, Sirolimus/adverse effects, Sirolimus/blood, Sirolimus/pharmacokinetics, Time Factors, Treatment Outcome
الوصف: PURPOSE: Sirolimus is a potent immunosuppressive agent used with increasing frequency in kidney transplantation. However, sirolimus can increase the rate of unexplained interstitial pneumonitis. The aim of this study was to evaluate the clinical characteristics of sirolimus-induced pneumonitis and the therapeutic results in renal transplant recipients. PATIENTS AND METHODS: Seventy-two patients received sirolimus, conversion or de novo regimen, at our center between January 2007 and April 2011. Twelve of the 72 patients (16.7%) developed interstitial pneumonitis. The patients were divided into three groups according to the following indications of sirolimus use: de novo, early conversion, and late conversion groups. RESULTS: The mean duration of follow-up was 11.0 짹 11.5 months. The mean blood level of sirolimus measured by microparticulate enzyme immunoassay was 16.5 짹 7.4 ng/mL at the time of diagnosis. The mean time from the start of sirolimus to pneumonitis onset was 14.7 짹 8.0 months. The clinical presentation included fever, cough, dyspnea, general weakness, and periorbital edema. In most cases, radiological imaging tests revealed bilateral lower-lobe involvement. Bronchoalveolar lavage was performed in three patients and two patients showed lymphocytic alveolitis. Sirolimus was discontinued or reduced for the treatment of pneumonitis. All cases of pneumonitis were resolved within 2 to 4 weeks. CONCLUSION: Sirolimus blood level should be monitored tightly and early intervention is important when sirolimus-induced pneumonitis is suspected. ; open
نوع الوثيقة: article in journal/newspaper
اللغة: unknown
تدمد: 0041-1345
1873-2623
العلاقة: TRANSPLANTATION PROCEEDINGS; J02755; OAK-2012-00644; https://ir.ymlib.yonsei.ac.kr/handle/22282913/91953Test; http://www.sciencedirect.com/science/article/pii/S0041134511016563Test; T201201165; TRANSPLANTATION PROCEEDINGS, Vol.44(1) : 161-163, 2012
الإتاحة: https://ir.ymlib.yonsei.ac.kr/handle/22282913/91953Test
http://www.sciencedirect.com/science/article/pii/S0041134511016563Test
حقوق: CC BY-NC-ND 2.0 KR ; https://creativecommons.org/licenses/by-nc-nd/2.0/krTest/
رقم الانضمام: edsbas.9B8A831F
قاعدة البيانات: BASE